背景:正常骨代谢有赖于成骨细胞介导的骨形成与破骨细胞介导的骨吸收之间的平衡,破坏该平衡会引发骨代谢相关疾病。微小RNA-146a(miR-146a)是一种非编码小分子RNA,在骨代谢中发挥重要作用。目的:就微小RNA-146a调控骨代谢的分子机制及...背景:正常骨代谢有赖于成骨细胞介导的骨形成与破骨细胞介导的骨吸收之间的平衡,破坏该平衡会引发骨代谢相关疾病。微小RNA-146a(miR-146a)是一种非编码小分子RNA,在骨代谢中发挥重要作用。目的:就微小RNA-146a调控骨代谢的分子机制及其在骨组织工程中的应用做一综述。方法:作者于2025年4月对中国知网、PubMed和Web of Science数据库中2000年1月至2025年4月发表的相关文献进行检索,中文检索词为“微小RNA-146a,骨,骨代谢,成骨细胞,破骨细胞,骨组织再生”;英文检索词为“microRNA-146a,Bone metabolism,Osteoblast,Osteoclast,Bone regeneration”,检索文献类型不限。共检索到文献11230篇,其中中国知网检索到中文文献988篇,PubMed数据库检索到英文文献5952篇,Web of Science数据库检索到英文文献4290篇。目标纳入研究骨代谢过程及其影响因素的相关文献,探究微小RNA-146a如何调控骨代谢过程、骨代谢关键细胞生物学行为的相关文献,微小RNA-146a应用于维持骨稳态、促进骨组织修复再生的相关文献;排除与文章主题相关度低、内容较陈旧、实验设计不严密、研究结果可信度较差、论证不充分的文献。最终根据文献排除标准筛选出与该综述主题密切相关且研究新颖、数据真实可信、论证充分、具有临床应用价值的90篇文献进行综述。结果与结论:①微小RNA-146a可通过抑制Wnt、Smad4、沉默信息调节因子2相关酶1等基因表达抑制成骨细胞形成及活性,或通过抑制肿瘤坏死因子受体相关因子6、白细胞介素1受体相关激酶1基因表达抑制破骨细胞形成,也可调节成骨细胞与破骨细胞的相互作用;②微小RNA-146a的异常表达可使成骨细胞和破骨细胞功能失调,打破骨代谢平衡,引发骨质疏松、骨关节炎、牙周炎等骨代谢相关疾病;③因此,微小RNA-146a可作为骨代谢相关疾病诊疗的潜在靶点,在骨代谢相关疾病治疗和骨组织工程中具有一定的应用前景。展开更多
Acute respiratory distress syndrome(ARDS)is a life-threatening condition that is characterized by high mortality rates and limited therapeutic options.Notably,Zhang et al demonstrated that CD146+mesenchymal stromal ce...Acute respiratory distress syndrome(ARDS)is a life-threatening condition that is characterized by high mortality rates and limited therapeutic options.Notably,Zhang et al demonstrated that CD146+mesenchymal stromal cells(MSCs)exhibited greater therapeutic efficacy than CD146-MSCs.These cells enhance epithelial repair through nuclear factor kappa B/cyclooxygenase-2-associated paracrine signaling and secretion of pro-angiogenic factors.We concur that MSCs hold significant promise for ARDS treatment;however,the heterogeneity of cell products is a translational barrier.Phenotype-aware strategies,such as CD146 enrichment,standardized potency assays,and extracellular vesicle profiling,are essential for improving the consistency of these studies.Further-more,advanced preclinical models,such as lung-on-a-chip systems,may provide more predictive insights into the therapeutic mechanisms.This article underscores the importance of CD146+MSCs in ARDS,emphasizes the need for precision in defining cell products,and discusses how integrating subset selection into translational pipelines could enhance the clinical impact of MSC-based therapies.展开更多
文摘背景:正常骨代谢有赖于成骨细胞介导的骨形成与破骨细胞介导的骨吸收之间的平衡,破坏该平衡会引发骨代谢相关疾病。微小RNA-146a(miR-146a)是一种非编码小分子RNA,在骨代谢中发挥重要作用。目的:就微小RNA-146a调控骨代谢的分子机制及其在骨组织工程中的应用做一综述。方法:作者于2025年4月对中国知网、PubMed和Web of Science数据库中2000年1月至2025年4月发表的相关文献进行检索,中文检索词为“微小RNA-146a,骨,骨代谢,成骨细胞,破骨细胞,骨组织再生”;英文检索词为“microRNA-146a,Bone metabolism,Osteoblast,Osteoclast,Bone regeneration”,检索文献类型不限。共检索到文献11230篇,其中中国知网检索到中文文献988篇,PubMed数据库检索到英文文献5952篇,Web of Science数据库检索到英文文献4290篇。目标纳入研究骨代谢过程及其影响因素的相关文献,探究微小RNA-146a如何调控骨代谢过程、骨代谢关键细胞生物学行为的相关文献,微小RNA-146a应用于维持骨稳态、促进骨组织修复再生的相关文献;排除与文章主题相关度低、内容较陈旧、实验设计不严密、研究结果可信度较差、论证不充分的文献。最终根据文献排除标准筛选出与该综述主题密切相关且研究新颖、数据真实可信、论证充分、具有临床应用价值的90篇文献进行综述。结果与结论:①微小RNA-146a可通过抑制Wnt、Smad4、沉默信息调节因子2相关酶1等基因表达抑制成骨细胞形成及活性,或通过抑制肿瘤坏死因子受体相关因子6、白细胞介素1受体相关激酶1基因表达抑制破骨细胞形成,也可调节成骨细胞与破骨细胞的相互作用;②微小RNA-146a的异常表达可使成骨细胞和破骨细胞功能失调,打破骨代谢平衡,引发骨质疏松、骨关节炎、牙周炎等骨代谢相关疾病;③因此,微小RNA-146a可作为骨代谢相关疾病诊疗的潜在靶点,在骨代谢相关疾病治疗和骨组织工程中具有一定的应用前景。
基金the Scientific and Technological Research Council of Türkiye(TÜBİTAK)Under the International Postdoctoral Research Fellowship Program(2219),No.1059B192400980the National Postdoctoral Research Fellowship Program(2218),No.122C158.
文摘Acute respiratory distress syndrome(ARDS)is a life-threatening condition that is characterized by high mortality rates and limited therapeutic options.Notably,Zhang et al demonstrated that CD146+mesenchymal stromal cells(MSCs)exhibited greater therapeutic efficacy than CD146-MSCs.These cells enhance epithelial repair through nuclear factor kappa B/cyclooxygenase-2-associated paracrine signaling and secretion of pro-angiogenic factors.We concur that MSCs hold significant promise for ARDS treatment;however,the heterogeneity of cell products is a translational barrier.Phenotype-aware strategies,such as CD146 enrichment,standardized potency assays,and extracellular vesicle profiling,are essential for improving the consistency of these studies.Further-more,advanced preclinical models,such as lung-on-a-chip systems,may provide more predictive insights into the therapeutic mechanisms.This article underscores the importance of CD146+MSCs in ARDS,emphasizes the need for precision in defining cell products,and discusses how integrating subset selection into translational pipelines could enhance the clinical impact of MSC-based therapies.
